文献速递心脑血管急症重症综合管理与镇静镇痛

左室压力最大上升速率在评估脓毒症诱导心肌病患者心功能中的价值

[The value of maximal rate of left ventricular pressure in evaluating cardiac function in patients with sepsis-induced cardiomyopathy].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论PiCCO参数dp/dtmax可作为床旁指标评估脓毒症诱导心肌病患者心功能,艾司洛尔控制心率可改善心功能并降低短期死亡率。

该单中心前瞻性随机对照研究纳入2020年4月1日至2022年2月28日天津市第三中心医院ICU收治的脓毒症/脓毒性休克成人患者,在完成1小时集束化治疗后行斑点追踪超声心动图(STE)和脉搏指示连续心排血量(PiCCO)监测,将心率>100次/分的患者随机分为艾司洛尔组和常规治疗组,每组55例。结果显示,艾司洛尔组24小时后全部达到目标心率,与常规治疗组相比,GLS、GEF、dp/dtmax显著升高,NT-proBNP显著降低,DO2和SV显著升高,SVRI显著升高。dp/dtmax与GLS在入ICU后24小时和48小时均呈负相关(r分别为-0.916和-0.935,均P<0.05)。艾司洛尔组28天死亡率30.9%(17/55) vs 常规治疗组49.1%(27/55),χ2=3.788,P=0.052,差异无统计学意义;但28天内死亡患者中使用艾司洛尔的比例低于存活患者[38.6%(17/44) vs 57.6%(38/66),χ2=3.788,P=0.040]。调整SOFA评分和DO2因素后,使用艾司洛尔的患者28天死亡风险显著低于未使用艾司洛尔的患者(OR=2.700,95%CI 1.038-7.023,P=0.042)。作者认为,PiCCO参数中的dp/dtmax简便易行,可作为床旁指标评估SIC患者心功能;艾司洛尔控制心率可改善SIC患者心功能并降低短期死亡率。

要点

  • 在完成1小时集束化治疗后心率>100次/分的脓毒症诱导心肌病患者中,艾司洛尔组24小时全部达到目标心率,且GLS、GEF、dp/dtmax较常规治疗组显著升高(均P<0.05)。
  • 艾司洛尔组NT-proBNP显著低于常规治疗组[μg/L:1 364.52(754.18,2 389.17) vs 3 508.85(1 433.21,6 988.12),P<0.05],DO2和SV显著升高(均P<0.05)。
  • PiCCO参数dp/dtmax与GLS在入ICU后24小时和48小时均呈负相关(r分别为-0.916和-0.935,均P<0.05),提示dp/dtmax可作为床旁评估SIC患者心功能的指标。
  • 艾司洛尔组28天死亡率30.9%(17/55) vs 常规治疗组49.1%(27/55),χ2=3.788,P=0.052,差异未达统计学显著;90天死亡率两组无显著差异。
  • 调整SOFA评分和DO2后,使用艾司洛尔的患者28天死亡风险显著低于未使用者(OR=2.700,95%CI 1.038-7.023,P=0.042)。

适用人群与场景

  • 天津市第三中心医院ICU于2020年4月1日至2022年2月28日收治的脓毒症/脓毒性休克成人患者,在完成1小时集束化治疗后行STE和PiCCO监测,其中心率>100次/分的患者被纳入随机分组。

诊断标准与关键阈值

  • 脓毒症/脓毒性休克诊断后完成1小时集束化治疗,且心率>100次/分。

处置流程与药物剂量

  • 在完成1小时集束化治疗后行STE和PiCCO监测,将心率>100次/分的患者随机分为艾司洛尔组和常规治疗组,每组55例。
  • 艾司洛尔组给予艾司洛尔控制心率,24小时后全部达到目标心率;常规治疗组给予常规治疗。
  • 所有患者在入ICU后6、24和48小时行STE和PiCCO监测,并计算APACHE II和SOFA评分。

研究设计与关键结果

  • 研究类型:单中心、前瞻性随机对照研究;样本量:每组55例,共110例;人群:脓毒症/脓毒性休克成人患者;干预:艾司洛尔控制心率 vs 常规治疗。
  • 主要终点:艾司洛尔组降低心率后dp/dtmax变化;艾司洛尔组24小时全部达到目标心率。
  • 与常规治疗组相比,艾司洛尔组GLS[(-12.55±4.61)% vs (-10.73±4.82)%]、GEF[(27.33±4.62)% vs (24.18±5.35)%]、dp/dtmax(mmHg/s:1 312.1±312.4 vs 1 140.9±301.0)显著升高,均P<0.05。
  • 艾司洛尔组NT-proBNP显著低于常规治疗组[μg/L:1 364.52(754.18,2 389.17) vs 3 508.85(1 433.21,6 988.12),P<0.05]。
  • 艾司洛尔组DO2[(mL×min-1×m-2):647.69±100.89 vs 610.31±78.56]和SV[(mL):49.97±14.71 vs 42.79±15.77]显著高于常规治疗组,均P<0.05。
  • 艾司洛尔组SVRI显著高于常规治疗组(kPa×s×L-1:287.71±66.32 vs 251.17±78.21,P<0.05),即使两组去甲肾上腺素剂量相似。
  • Pearson相关分析显示,dp/dtmax与GLS在入ICU后24小时和48小时均呈负相关(r分别为-0.916和-0.935,均P<0.05)。
  • 艾司洛尔组28天死亡率30.9%(17/55) vs 常规治疗组49.1%(27/55),χ2=3.788,P=0.052,差异无统计学意义;28天内死亡患者中使用艾司洛尔的比例低于存活患者[38.6%(17/44) vs 57.6%(38/66),χ2=3.788,P=0.040];艾司洛尔对90天死亡率无影响。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性随机对照研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,PiCCO参数中的dp/dtmax简便易行,可作为床旁指标评估脓毒症诱导心肌病患者的的心功能。
  • 作者认为,艾司洛尔控制脓毒症诱导心肌病患者的心率可改善心功能并降低短期死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the value of maximal rate of left ventricular pressure (dp/dtmax) in evaluating the changes of cardiac function before and after heart rate reduction in patients with sepsis-induced cardiomyopathy (SIC).

METHODS: A single-center, prospective randomized controlled study was conducted. Adult patients with sepsis/septic shock admitted to the department of intensive care unit (ICU) of Tianjin Third Central Hospital from April 1, 2020 to February 28, 2022 were enrolled. Speckle tracking echocardiography (STE) and pulse indication continuous cardiac output (PiCCO) monitoring were performed immediately after the completion of the 1 h-Bundle therapy. The patients with heart rate over 100 beats/minutes were selected and randomly divided into esmolol group and regular treatment group, 55 cases in each group. All patients underwent STE and PiCCO monitoring at 6, 24 and 48 hours after admission in ICU and calculated acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure assessment (SOFA). Primary outcome measure: change in dp/dtmax after reducing heart rate by esmolol. Secondary outcome measures: correlation between dp/dtmax and global longitudinal strain (GLS); changes of vasoactive drug dosage, oxygen delivery (DO2), oxygen consumption (VO2) and stroke volume (SV) after the administration of esmolol; proportion of heart rate reaching the target after the administration of esmolol; 28-day and 90-day mortality in two groups.

RESULTS: Baseline data on age, gender, body mass index, SOFA score, APACHE II score, heart rate, mean arterial pressure, lactic acid, 24-hour fluid balance, sepsis etiology and prior comorbidities were similar between esmolol group and regular treatment group, there were no significant differences between the two groups. All SIC patients achieved the target heart rate after 24 hours of esmolol treatment. Compared with regular treatment group, parameters reflecting myocardial contraction such as GLS, global ejection fraction (GEF) and dp/dtmax were significantly increased in esmolol group [GLS: (-12.55±4.61)% vs. (-10.73±4.82)%, GEF: (27.33±4.62)% vs. (24.18±5.35)%, dp/dtmax (mmHg/s): 1 312.1±312.4 vs. 1 140.9±301.0, all P < 0.05], and N-terminal pro-brain natriuretic peptide (NT-proBNP) significantly decreased [μg/L: 1 364.52 (754.18, 2 389.17) vs. 3 508.85 (1 433.21, 6 988.12), P < 0.05], DO2 and SV were significantly increased [DO2 (mL×min-1×m-2): 647.69±100.89 vs. 610.31±78.56, SV (mL): 49.97±14.71 vs. 42.79±15.77, both P < 0.05]. The system vascular resistance index (SVRI) in esmolol group was significantly higher than that in regular treatment group (kPa×s×L-1: 287.71±66.32 vs. 251.17±78.21, P < 0.05), even when the dosage of norepinephrine was similar between the two groups. Pearson correlation analysis showed that dp/dtmax was negatively correlated with GLS in SIC patients at 24 hours and 48 hours after ICU admission (r values were -0.916 and -0.935, respectively, both P < 0.05). Although there was no significant difference in 28-day mortality between esmolol group and regular treatment group [30.9% (17/55) vs. 49.1% (27/55), χ2 = 3.788, P = 0.052], the rate of esmolol use in patients who died within 28 days was lower than that in patients who survived [38.6% (17/44) vs. 57.6% (38/66), χ2 = 3.788, P = 0.040]. In addition, esmolol has no effect on the 90-day mortality of patients. Logistic regression analysis showed that after adjusting for SOFA score and DO2 factors, patients who used esmolol had a significantly lower risk of 28-day mortality compared with patients who did not use esmolol [odds ratio (OR) = 2.700, 95% confidence interval (95%CI) was 1.038-7.023, P = 0.042].

CONCLUSIONS: dp/dtmax in PiCCO parameter can be used as a bedside indicator to evaluate cardiac function in SIC patients due to its simplicity and ease of operation. Esmolol control of heart rate in SIC patients can improve cardiac function and reduce short-term mortality.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Wang J, He Z, Gao X, et al. [The value of maximal rate of left ventricular pressure in evaluating cardiac function in patients with sepsis-induced cardiomyopathy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37366129. doi:10.3760/cma.j.cn121430-20220412-00362

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。